Phase 2Recruiting
Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells (MSV_LE)
Phase II, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Safety and Efficacy of Mesenchymal Stem Cells (MSV-allo) in the Treatment of Lupus Nephritis
- Sponsor
- Red de Terapia Celular (Industry)
- Enrollment
- 20 planned
- Conditions
- Lupus Nephritis; Lupus Erythematosus
- Interventions
- Mesenchymal stem cells (MSC); Placebo
- Ages
- adults, older adults
- Registry
- NCT03673748, EUCTR2022-000243-80
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MSCs) in achieving a full or partial response in the treatment of Lupus Nephritis (LN) during its induction period.
Primary outcomes
- Proportion of patients who have achieved complete response
- Proportion of patients who have achieved partial response
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered